minimal residual disease (MRD). Therefore, the recovery of ccfDNA in sufficient quantity and adequate purity is crucial to provide accurate and reproducible results. In this study, we investigate the efficiency of four different commercial kits to recover short fragments of DNA compatible with the ccfDNA. **Methods:** Ten mL of total peripheral blood from seven patients with Diffuse Large B-Cell Lymphoma (DLBCL) were collected in EDTA and were immediately processed. Plasma was obtained by centrifugation at 1.900 x g for 10 min at 4 °C, followed by other centrifugation at 20.000 x g for 10 min at 4 ° C to remove cellular debris. Aliquots of 1.0 mL of plasma were stored at -80 °C until ccfDNA extraction. The ccfDNA extraction was performed using the same samples by the following kits: QIAamp MinElute ccfDNA kit (CFDNA - Qiagen, Hilden, Germany), QIAamp DNA Mini Kit (QBLOOD - Qiagen, Hilden, Germany), Illustra Blood GenomicPrep Mini Spin Kit (GE - GE Healthcare Bio-Sciences Corp, UK) and ccfDNA isolation kit Quick-ccfDNA Serum & Plasma Kit (ZYMO - Zymo Research, Irvine, USA) according to the manufacturer's recommendations. The ccfDNA obtained was eluted in 30 μL of elution buffer for the subsequent experiments. The measurement of the ccfDNA obtained for each kit was performed in a Qubit 2.0 fluorometer using Qubit dsDNA HS assay kit (Thermo Fischer Scientific, Waltham, USA). The analysis of integrity, purity and the size of the fragments of DNA were performed in the Agilent 2100 Bioanalyzer (Agilent Technologies, Germany) equipment using the High Sensitivity DNA kit (Agilent Technologies, Germany). **Results:** The results obtained for each commercial kit in the Qubit-analysis were: *CFDNA* (0.27 ng/uL), *QBLOO* D (0.26 ng/uL), *ZYMO* (0.03 ng/uL) and *GE* (0.02 ng/uL). The Bionalyzer eletrophoresis showed that *CFDNA* kit was able to recover two different fragments sizes of ccfDNA one of 360–380 bp (0.114 ng/uL) and other of 160-180 bp (1.808 ng/uL). The DNA recovered with *QBLOOD* revealed sizes of 360-380 bp (0.031 ng/uL) and 160-180 bp (0.079 ng/uL). Both kits, *GE* and *ZYMO* were not able to isolate fragments of DNA smaller than 10.380 pb. **Conclusion:** We demonstrated that *QIAamp MinElute ccfDNA* kit (*CFDNA*) was capable to recovery high quantity of small fragments of DNA compatible with ccfDNA. This result supports the use of protocols based in magnetic beads in experiments working with ccfDNA. Additionally, we highlight the importance to verify the quality and not only the quantity of the DNA extracted to confirm the presence of ccfDNA.

https://doi.org/10.1016/j.htct.2021.10.723

COEXISTENCE OF ACUTE MONOBLASTIC LEUKEMIA IN A CHRONIC LYMPHOCYTIC LEUCEMIA: CASE REPORT

P Vicari, VM Sthel, VC Queiroz, SS Ioguy, KMS Lacerda, CC Cabral, S Tufik

Associação Fundo de Incentivo à Pesquisa (Afip) - Medicina Diagnóstica, São Paulo, SP, Brazil

Background: Chronic lymphocytic leukemia (CLL) is associated with an increased risk of other malignancies, such as skin and. second hematological malignancies. In the majority of cases, this usually involves a disease transformation to an aggressive non-Hodgkin lymphoma, multiple myeloma or prolymphocytic lymphoma. CLL patients can rarely develop acute myeloid leukemia (AML). We have reported a case in which there was simultaneous presentation of AML and CLL. **Case report:** A 78-year-old man presented with tiredness and mucosal bleeding. Laboratory evaluation revealed a white blood count of 220,970 μ/l with 4% of blasts,69% lymphocytes and 20% monocytes, hemoglobin of 6.7 g/dl, platelet count of 29,000 μ/l. A bone marrow aspirate revealed markedly hypercellular bone marrow with 21% blasts and promonocytes and 47% mature lymphocytes. A peripheral blood flow cytometry demonstrated a mature CD5 and CD23 positive B-cell population expressing CD19, low-density CD 20, CD11c, CD25, CD81, CD39 and lambda light chains at 53.02% of lymphocytes, consistent with B-CLL.; In addition, a second population showed CD33, CD13 low-density, CD11b, CD64, CD14, CD36, HLA-DR, CD56, CD123, CD11c, CD38 and CD9 positives in 39.35% of immature monocytes, consistent with acute monoblastic leukemia. Cytogenetics on bone marrow aspirate showed 48,XY, +4,+8[18] / 46,XY [2]. **Conclusion:** The present report highlights the rare possibility of the development of a myeloid malignancy in a patient with lymphoid malignancy. Most of these cases more frequently present as a secondary event in patients receiving chemotherapeutic agents for CLL.Knowledge of this rare association is the key to timely and accurate diagnosis, particularly in patients with atypical presentation. Existing literature demonstrates that AML may also develop concurrently or even after the diagnosis of treatment-naïve CLL patients. Further studies of such patients have potential to provide insight into the pathogenesis of myeloid as well as lymphoid malignancies.

https://doi.org/10.1016/j.htct.2021.10.724

COMPARAÇÃO ENTRE DUAS DIFERENTES CALCULADORAS ONLINE DE FARMACOCINÉTICA (WAPPS-HEMO VERSUS MYPKFIT)

DRC Silva, LC Resende, VE Oliveira, NDSR Santos, ANL Prezotti, AR Neto, DMDC Rocha, MPSV Orletti, JSM Duarte, SS Marcondes

Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos (HEMOES), Vitória, ES, Brasil

Introdução: A farmacocinética (PK) de fatores FVIII e FIX é essencial para a individualização da profilaxia em pacientes hemofílicos. O cálculo da meia-vida e do tempo superior à 1% são estimados por diferentes programas de farmacocinéticas, onde são introduzidos algoritmos matemáticos e podem ser utilizados para várias drogas. Nos últimos anos foram desenvolvidos softwares que realizam uma modelagem multicompartimental de uma derivação Bayesiana para estimativa de dados. **Objetivo:** Avaliar o desempenho e comparar curvas farmacocinéticas utilizando duas calculadoras diferentes, disponibilizadas na Web, para determinar a meia-vida e o tempo superior a 1% do Fator VIII recombinante (rFVIII)